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Abstract 
The molecular defects in the HEXB gene encoding the common /3-subunit of lysosomal /3-hexosaminidase A (/3-Hex A, a/3) and 
/3-Hex B (13/3) were investigated in a Portuguese family affected with late onset Sandhoff disease (GM2-gangliosidosis variant 0). This 
family comprised two unaffected daughters and three affected sibs who developed at about age 17 cerebellar taxia and mental deficiency. 
Their parents were consanguineous and clinically asymptomatic. There was no detectable /3-Hex B activity and a profound reduction in 
the activity of /3-Hex A in the leukocytes and transformed lymphoid cell lines from the affected sibs. The expected intermediate values 
were observed in the parents as well as in one daughter and her children. Western analysis revealed the presence of reduced, but 
detectable amounts of mature /3-chain protein in cell lysates from the probands and intermediate l vels in the parents. Nucleotide 
sequencing of amplified, reverse-transcribed /3-chain mRNA demonstrated the presence of two single point mutations: an A 619 to G 
transition in exon 5 (Ile 2°7 ---> Val), and a G 1514 to A transition in exon 13 (Arg 5°5 --* Gin). Both of these two mutations have been 
previously linked to the adult form of Sandhoff disease in compound heterozygote patients. All three affected sibs were found to be 
homoallelic for both mutations. Interestingly, while the mother was heterozygous for each mutation, the father was homozygote for the 
ArJg~ G substitution and heterozygote for the G 1514 ---~ A transition. Since the father is homozygote for the m 619---~ G mutation but 
expresses a biochemical phenotype consistent with a carrier of Sandhoff disease and is clinically asymptomatic, this substitution is likely 
a neutral mutation. We confirmed this hypothesis by finding this transition present in 4 of 30 alleles from normal individuals. We 
conclude that homozygosity for the G 1514 _...> A mutation is exclusively responsible for the adult form of Sandhoff disease in this family, 
and that the A 619 --~ G substitution is not a deleterious mutation but rather a common HEXB polymorphism. 
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I. Introduction 
Abbreviations: /3-Hex, /3-hexosaminidase; 4-MU-GIcNAc, 4-methyl- 
umbelliferyl-2-acetamido-2-deoxy-/3-D-glucopyranoside; 4-MUGS, 4- 
methylumbelliferyl-6-sulfo-2-acetamido-2-deoxy-~-D-glucopyranoside; 
PCR, polymerase chain reaction; RFLP, restriction fragment length poly- 
morphism; PSM, PCR-mediated site-directed mutagenesis 
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Lysosomal /3-hexosaminidases (/3-Hex; EC 3.2.1.52) 
are widely distributed hydrolases involved in the degrada- 
tion of glycolipids, glycoprotein-derived oligosaccharides 
and glycosaminoglycans [1]. /3-Hex consists of two major 
isoenzymes, Hex A which is composed of an a- and 
/3-subunit, and Hex B composed of two /3 subunits. Al- 
though there are distinct active sites in each subunit, 
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dimerization is required in order for either to become 
functional. The active site of c~-subunit catalyzes the hy- 
drolysis of GM2 ganglioside; however, in vivo the presence 
of the /3-subunit in the Hex A heterodimer and the small 
GM2 activator protein is also required for this function. As 
well the a-active site is responsible for the hydrolysis of 
other negatively charged natural and artificial substrates, 
e.g. 4-MUGS. Unlike GM2 ganglioside, the latter water- 
soluble compounds are also substrates for homodimeric 
Hex S (an)  which is an unstable isozyme found in small 
amount in samples from patients who are unable to synthe- 
size a functional /3-subunit. On the other hand, the /3-sub- 
unit cleaves a variety of neutral, water-soluble substrates 
including the common substrate 4-MU-GlcNAc. 
Deleterious mutations in the HEXB gene, located on 
chromosome 5, which encodes the common /3-subunit, 
result in Sandhoff disease (GM2 gangliosidosis variant 0; 
MIM # 268800) [1,2]. Thus, Sandhoff disease is character- 
ized by deficient activities of both Hex A and Hex B, 
leading to tissue accumulation of GM2 ganglioside and 
other glycolipids, as well as urinary excretion of oligo- 
saccharides. 
Based on the age of onset of clinical symptoms, differ- 
ent clinical phenotypes can be classified into infantile, 
juvenile and adult forms of Sandhoff disease. Whereas the 
classical infantile form is a rapidly fatal neurological disor- 
der, late-onset forms are compatible with a long survival. 
The severity of Sandhoff disease seems to correlate with 
the residual activity against GMz ganglioside [3]. The 
nature of the molecular defects underlying the heterogene- 
ity and pathophysiology of Sandhoff disease is still poorly 
known. In particular, only a few mutations have been 
characterized in patients affected with late-onset forms of 
the disease. To date these have been either mutations that 
affect mRNA splicing or substitution mutations, all of 
which allow the formation of low levels of Hex A activity 
[4-11 ]. In addition, most of the patients have been found 
to be compound heterozygotes (the second allele being 
sometimes null, e.g. a common partial gene deletion [12] 
or not determined). Homoallelism has been described in 
only one patient [8]. 
In this study, we report he identification of the molecu- 
lar alterations present in a family comprising three patients 
affected with the adult form of Sandhoff disease. This 
family was selected for genetic studies because the pa- 
tients' parents were consanguineous, so that homoallelism 
would be expected in the affected subjects, thus permitting 
a genotype/phenotype correlation to be made. 
2. Subjects and methods 
2.1. Family history 
Patients (11-3, 11-4 and 11-5, see pedigree in Fig. 1) were 
three of five siblings of a consanguineous Portuguese 
family (the grandfathers of the parents were first cousins). 
All presented at 17-18 yr of age with a progressive 
spinocerebellar syndrome with a slight mental deficiency. 
The oldest one (patient 1I-3) was severely affected with 
loss of motor autonomia, static tremor, horizontal nystag- 
mus, upper limb amyotrophy and mental deficiency. His 
brother (patient 11-4) had walking difficulties, no amyotro- 
phy but frequent spontaneous fasciculations. Although 
brain MR imaging showed a clear cerebellar atrophy, the 
patient presented a moderate cerebellar syndrome. The 
affected sister (patient II-5) also had a cerebellar syndrome 
and a limited mental efficiency. Thin-layer chromato- 
graphic analysis of the urine of patients 11-3, 1I-4 and 1I-5 
did not demonstrate abnormal excretion of oligosaccha- 
rides. 
Repeated clinical examination of the patients' parents 
(I-1 and I-2) and sisters (II-1 and II-2) showed that they 
were unaffected. 
2.2. Isolation of  leukocytes and cell culture 
Leukocytes from heparinized blood were isolated using 
PlasmageU M (Roger Bellon Lab., Paris, France) [13]. Lym- 
phoid cell lines were established by Epstein-Barr virus- 
transformation of blood B lymphocytes obtained from 
control individuals and from our patients [14]. Lymphoid 
cells were grown in a humidified 5% CO 2 atmosphere at
37°C in RPMI 1640 medium (Gibco BRL, Cergy-Pontoise, 
France) supplemented with L-glutamine (2 mmol/1), peni- 
cillin (100 U/ml), streptomycin (100/xg/ml) and heat-in- 
activated fetal calf serum (10%) as previously reported 
[ 15-17]. Cells were harvested by low-speed centrifugation 
and washed 3-times with PBS. Cell pellets were kept 
frozen at -70°C until use. 
2.3. Enzyme studies 
Total /3-Hex activity was determined in plasma and in 
extracts of peripheral blood leukocytes and Epstein-Barr 
virus-transformed lymphoid cells with 4-MU-GlcNAc as 
substrate [17]. Hexosaminidase isoenzymes were assayed 
by the thermodenaturation assay method [18]. Hex A activ- 
ity was also specifically determined using 4-MUGS as 
substrate [19]. 
2.4. Western blot analysis 
The proteins in samples of cell lysates (30 /zg each) 
were separated by SDS-PAGE and analyzed utilizing the 
Amersham ECL system as previously described [7]. A 
rabbit anti-human Hex B IgG preparation was used as the 
primary antibody. 
2.5. PCR and sequencing 
Genomic DNA was prepared from leukocyte and lym- 
phoid cell pellets [20]; total cellular RNA was extracted 
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Fig. 1. Pedigree of the adult Sandhoff amily described in the present 
study. The total plasma /3-hexosaminidase activity (expressed aspercent- 
age of the normal value, 815+ 150 nmol/h per ml) is indicated in 
brackets. Squares indicate males; circles, females. Solid and half-solid 
symbols correspond to homozygous and heterozygous enzymatic status, 
respectively, n.d., not determined. 
from lymphoid cells by a guanidinium isothiocyanate de- 
rived procedure using RNA-B'M (Bioprobe Systems, Mon- 
treuil, France) according to the manufacturer's instruc- 
tions. Genomic DNA and cDNA were amplified by PCR 
using different pairs of primers as described [5,6,8,9]. 
Amplif ied fragments were sequenced irectly, by fluores- 
cent dye terminator cycle sequencing (Applied Biosys- 
terns) according to the manufacturer's instructions, and 
analysed on an automated DNA sequencer (Applied 
Biosystems). 
2.6. Ava I restriction fragment length polymorphism 
(RFLP) studies 
PCR products obtained with pr imers 5 ' -CT-  
TGTCTATGGGGAGAATAT-Y  (sense)  and 5'- 
TCAGTCTGTCATAGGCGTCA-3 '  (antisense) were di- 
gested with directly added 20 U of AvaI (Gibco BRL Life 
Technologies, Eragny, France) and incubated for 2 hours 
at 37°C. Digestion products were analysed on a 10% 
polyacrylamide (29:1) non denaturing gel after 2 hours 
under constant current (25 mA). 
2.7. PCR-mediated site-directed mutagenesis (PSM) 
PCR was performed on cDNA using the following 
o l igonuc leot ide  pr imers :  5 ' -GCTGAATTCCAG-  
GCTAAAACCCA-3'  (sense) and 5 ' -GCAGATAATGTC-  
TGGATGTATGAA-3 '  (antisense). Amplif ied fragments 
were digested for 2 hours with 20 U of HinfI (Gibco BRL 
Life Technologies) and electrophoresed on 10% polyacryl- 
amide (29: 1) for 2 hours at 45 mA. 
3. Results 
As illustrated in Fig. 1 and Table 1, our patients with 
adult Sandhoff, i.e. the two clinically affected brothers 
(patients 1I-3 and I1-4) and their affected sister (patient 
II-5) exhibited clearly reduced levels of total /3-hexosa- 
minidase activity in plasma, peripheral blood leukocytes 
and Epstein-Barr virus-transformed lymphoid cells. The 
determination of the /3-Hex B activity in cells from all 
three symptomatic patients howed a severe deficiency of 
this isoenzyme (Table 1), indicating their homozygote 
status for GM2 gangliosidosis variant 0 (Sandhoff disease). 
This conclusion was further corroborated by the finding of 
a considerably decreased /3-Hex A activity in leukocytes 
and lymphoid cells (Table 1), as well as in plasma (data 
Table 1 
Activities of total /3-hexosaminidase ndfl-hexosaminidase i oenzymes in blood leukocytes and Epstein-Barr virus-transformed lymphoid cells from 
members of the affected family 
Patient Leukocytes Lymphoid cell lines 
Total Hex Hex B Hex A a Total Hex Hex B Hex A a 
(U b) (% of total) (U b) (U b) (% of total) (U b) 
I-1 n,d. n.d. 321 10 63 
1-2 n,d. n.d. 299 9 54 
II-1 1101 48 65 523 19 113 
1I-2 755 27 41 376 11 70 
I1-3 123 0 12 180 2 30 
11-4 155 0 14 149 0 23 
1I-5 104 0 10 151 1 32 
III- 1 1584 43 99 
111-2 1436 49 71 
111-3 629 27 36 
Ili-4 500 26 29 
Controls 1205 + 200 54 + 8 74 ___ 15 558 + 85 35 + 6 107 + 18 
Total fl-hexosaminidase ctivity was assayed with 4-MU-GIcNAc as substrate; Hex B was determined with the same substrate after thermodenaturation 
[18]. Hex A activity was assayed with 4-MUGS as substrate. For each patient, the activity of another lysosomal enzyme (fl-galactosidase or
fl-glycuronidase) was simultaneously measured and found to be normal. Each determination was performed atleast in duplicate and, whenever possible, on 
different cell batches. 
These values also include Hex S activity 
b nmol of methylumbelliferone rel ased per h and per mg of cell protein. 
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Fig. 2. Western blot of lymphoid cell lysates. The amount of total ysate 
protein loaded from each cell line was 30 /zg. Extracts were from the 
members of our adult Sandhoff amily, two different controls (N) and one 
patient with infantile Sandhoff disease homozygous for a deletion muta- 
tion (SD). The position of the mature, lysosomal /3 subunit (28 kDa) is 
indicated. 
not shown). Intermediate values were found in their par- 
ents and in one sister (11-2) and her children (1II-3 and 
III-4), consistent with a heterozygote status (Fig. 1 and 
Table 1). Normal levels of total /3-Hex, /3-Hex A and 
/3-Hex B activities were observed in the other sister (II-1) 
and her children (III-1 and 111-2), which were suggestive of 
a non carrier status. 
The relative steady state level of mature, lysosomal, 
/3-subunit of Hex B protein in lymphoid cells from the 
members of our family was estimated by Western blot 
analysis. Fig. 2 demonstrates that the amount of mature 
/3-protein contained in cell lysates from our probands (11-3, 
11-5) was greatly reduced, but clearly detectable, when 
compared with similar amounts of total protein from nor- 
mal cell lysates. In contrast, as previously observed, /3-pro- 
tein was undetectable in a cell lysate from an infantile 
Sandhoff patient [7]. Fig. 2 also shows that cells from the 
older sister (II-1) with normal levels of Hex activities also 
contained a normal amount of mature /3-subunits, and that 
cells from the obligate carrier-parents had about 50% of 
the control levels, again consistent with the enzyme activ- 
ity measurements. 
To identify the molecular basis of the /3-Hex B defect 
in this family, direct nucleotide sequencing was performed 
on overlapping PCR-fragments from reverse-transcribed 
/3-mRNA and/or  genomic DNA from lymphoid cells of 
the probands (patients II-3, 11-4 and 11-5). For each patient, 
different PCR products from separate xtractions of lym- 
phoid cells were analyzed. The different overlapping frag- 
ments encompassing the whole cDNA of the HEXB gene 
were shown to be amplified by PCR and of the expected 
size. Thus, there were likely no large deletions or insertion 
present. We then determined the nucleotide sequence of all 
the amplified fragments. Two single alterations were de- 
tected in double-dose in the probands. The first was an A 
to G transition which occurred at position 619 of exon 5 of 
the HEXB gene (see Ref. [21] for numbering) (Fig. 3, 
patient II-3), which caused an Ile 2°7 to Val amino acid 
substitution. The second alteration was a G to A substitu- 
tion at position 1514 of exon 13. This would result in an 
Arg 5°5 to Gln substitution in the protein (Fig. 3, patient 
1I-3). These two single base substitutions were found in 
PCR fragments amplified from both the cDNA and ge- 
nomic DNA of patients I1-3, and also I1-4 and I1-5 (data 
not shown). The remainder of the coding sequence was 
completely normal. 
The observation that the G~514 ~ A transition destroys 
an Aval  restriction site was used to screen the entire 
family for this mutation. The digestion was carried out on 
both cDNA (data not shown) and genomic DNA (Fig. 4) in 
order to determine if there was also a mRNA-negative 
allele present. With genomic DNA, patients II-3, II-4 and 
II-5 were shown to be homozygotes for the G 1514''-) A 
transition (Fig. 4). A clear heterozygote pattern was found 
TGTATCAACCAAAAT ACTI"GCCTGAGGCCA 
diagnosis: adult Sandhoff disease 
coding 
sequence: AI"r TTG GTT GAT ACA 
amino acid: Va1207 
1 1 
TGTATCAATCAAAAT AcI'rGCCCGAGGCCA 
patient: control 
diagnosis: no g-Hex deficiency 
i coding 
sequence: AT'£ TTG AT'I" GAT ACA 
amino add: Ile 207 
patient:. II-3 
diagnosis: adult Sandhoff disease 
coding 
sequence: TGG CCT CAG GCA AGT 
amino add: Gln 505 
patient: control 
diagnosis: no t?,-Hex deficiency 
coding 
sequence: TGG CCT CGG GCA AGT 
amino acid: Arg 505 
Fig. 3. Identification f the A 619 ~ G and G L5i4 --~ A mutations in the HEXB cDNA prepared from lymphoid cell lines. The diagrams show the raw data 
from an automatic DNA sequencer. In each figure, the nucleotide s quence shown is that of the non-coding strand. The arrow indicates the mutant site. 
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Fig. 4. AeaI restriction fragment length polymorphism analysis. Chromo- 
somal DNA was prepared from lymphoid cell lines and amplified by PCR 
with primers to obtain a 260 bp fragment containing the G 15~4 ---~A 
transition. Digestion by At~aI resulted in fragments of 186 and 74 bp in 
case of normal genomic DNA while no digestion of the amplified 
fragment occurred when the mutation was present. The DNA marker used 
is pGEM (Promega). 
for both their parents (I-1 and 1-2), thus eliminating the 
possibility of deleted chromosomal DNA at the mutant 
locus. The two other siblings appeared either not to carry 
the mutant allele (subject II-1) or to be heterozygote for it 
(subject I1-2). 
Unlike the G 1514 ~ A transition, the A 619 ~ G mutation 
neither creates nor destroys a restriction enzyme site. 
Therefore, we used two methods to confirm its existence. 
We first used the PSM technique. It is a non isotopic 
technique allowing rapid detection of point mutations [22]. 
The 3' end of the reverse primer included a single base 
mismatch designed to alter the sequence of the amplified 
product. PSM gives rise to products carrying a novel 
restriction site for the enzyme Hinfl. This restriction site is 
associated with the wild-type allele but not with the mutant 
allele. Using this methodology, patients II-3, II-4 and II-5 
again appeared to be homozygotes for the A 6~9 ~ G muta- 
tion (Fig. 5). The mother (I-2) and one asymptomatic 
daughter (II-2) were shown to be heterozygotes, with only 
one digested allele. Unexpectedly, the healthy father (I-l) 
was found to be homozygote for this mutation (Fig. 5). 
Furthermore, the clinically as well as biochemically nor- 
mal daughter (II-1), who did not carry the G 1514"--~ A
transition, was found to be heterozygote for the A6~9~ G 
mutation. Identical genotypes could also be assigned to 
these individuals from the results obtained using another 
method, i.e., allele-specific oligonucleotide hybridization, 
57 
36 
27 
21 
Fig. 5. Use of PCR-mediated site-directed mutagenesis (PSM) to detect 
the A619~ G mutation, cDNA was prepared from lymphoid cell lines of 
a normal subject and members of our Sandhoff family, and amplified by 
PCR with the primers given in Section 2 to obtain a fragment of 297 bp. 
Digestion by Hinfl resulted in fragments of 105, 93, 36, 27, 21 and 15 bp 
in case of normal cDNA. In the presence of the mutation, the amplified 
cDNA was digested into fragments of 105, 93, 57, 27 and 15 bp. 
employing digoxigenin-labelled oligonucleotides (data not 
shown). 
These surprising data were further confirmed by se- 
quencing genomic DNA extracted from blood leukocytes 
and/or lymphoid cells derived from the father. A homozy- 
gote pattern for the A 6j9 ~ G mutation was observed in the 
father, identical to those found in the probands (data not 
shown). Similar results were obtained on the genomic 
DNA extracted from a newly established lymphoid cell 
line. A heterozygote pattern was found in subject II-1 (data 
not shown). The inheritance of the two molecular alter- 
ations of HEXB gene we identified in our adult Sandhoff 
family is summarized in Fig. 6. 
4. Discussion 
This study reports a Portuguese family with an adult 
form of Sandhoff disease associated with two point muta- 
tions. Both of these alterations have previously been docu- 
mented in separate reports of two patients with late-onset 
forms of Sandhoff disease. One adult Sandhoff patient was 
heterozygous for the G j514----) A mutation and a partial 
HEXB gene deletion [9]. The other was also a compound 
heterozygote for the A6~9~ G mutation and a missense 
mutation at codon 456 encoding a Tyr ~ Ser substitution. 
The fl-chains carrying the latter substitution are trapped in 
the endoplasmic reticulum and degraded [6]. 
Although our Sandhoff patients had two previously 
described mutations, our observations are unique for two 
reasons. First, the two point mutations were present in the 
1 
Asymptomatie ksymptomatic 
[ ]  NO MUTATION 
• 619 A-->G 
• 1514 G-->A [ 4 5 
II ! 
Asymptomatie Adult Adult Adult 
Asymptomatie $andhoff S~dhoff $andhoff 
Fig. 6. Summary ofinheritance of mutant alleles and clinical presentation n the present Sandhoff family. For each individual, the left and right parts of the 
symbol correspond to the two different HEXB alleles. 
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same allele and our three clinically affected patients were 
shown to be homoallelic for the two defects. Secondly, we 
demonstrate that the father (aged 60), who still remains 
asymptomatic, is homozygous for the A 619 ~ G transition, 
which raises the question of its physiological significance. 
The conclusion that both the A 619 ~ G and the G 1514 ---, 
A substitutions are carried by the same allele is based on 
nucleotide sequencing of both cDNA and genomic DNA 
from the probands, and sequencing, AvaI digestion and 
PSM of DNA from the patients' parents. All of which 
indicated the mother's carrier status for both mutations. 
The fact that our probands are homoallelic was not unex- 
pected since their parents are consanguineous. 
Much more surprising was the observation that the 
father, who is heterozygote for the G 1514 --) A substitution, 
is also homozygote for the A 619 ---> G transition. This find- 
ing was confirmed by nucleotide sequencing (by both 
manual and automated methodologies) of the patients' 
father's cDNA and genomic DNA, as well as PSM and 
allele-specific oligonucleotide hybridization. The presence 
in the father of two mutated sequences for exon 5 might be 
caused either by homozygosity for this mutation, or by a 
heterozygosity for a partial gene deletion. However, the 
latter possibility was excluded because two species of 
mRNA encoding the /3-chain were detected, i.e., the G 1514 
A mutant and the normal alleles were found after 
reverse-transcription of both parents' mRNA. Moreover, 
the homozygosity of the father is corroborated by the 
genotype we determined for one of the asymptomatic 
daughters, II-1 (see Fig. 6). This daughter was shown not 
to carry the G 1514 ---) A mutation, but to be heterozygote 
for the A 619 --') G transition. Such a genotype can be ex- 
plained only by inheritance of a normal allele from her 
mother and an allele carrying only the A 619 ~ G mutation 
from the father. 
Comparing our data to previously published observa- 
tions [6,9,10] suggest hat a reevaluation of the physio- 
logical consequences of these HEXB mutations is neces- 
sary. The G 1514 ~ A mutation was shown to be responsi- 
ble for a labile /3-Hex B as demonstrated by expression in 
COS cells [9]. This defect was reported to be likely 
responsible for a late-onset form of GM2 gangliosidosis, 
since it was found in combination with a null allele [9]. 
This conclusion is in accordance with our findings that 
only our three patients who are homoallelic for this muta- 
tion express an adult phenotype. Moreover, intermediate 
levels of Hex B and Hex A activities were found only in 
the individuals heterozygote for the G1514--* A mutation 
(see Table l and Fig. 6). Additionally, our data suggest 
that the G 1514 ---) A allele produces very little heat-labile 
mutant Hex B activity (1-2%) in patient cells, as opposed 
to being highly expressed in transiently transfected COS 
cells [9]. This conclusion is based on the similar levels of 
Hex B that were obtained for any of our unaffected 
patients regardless of genotype (see Table 1) by using 
either the common substrate assay with (Hex B) and 
without (Hex A, B and S) heat denaturation (in this assay, 
any heat-labile Hex B as well as Hex S would be scored as 
Hex A) or by calculating the ratio of activities produced 
from the common (Hex B, A and S) versus the a-specific 
(Hex A and S) substrates, i.e. units of 4-MUGS/4-MU- 
GIcNAc. As well the levels of/3-Hex activity (Table 1) in 
the patients' cells correlates with the levels of mature 
/3-CRM as seen in Western blot analysis (Fig. 2). Thus, 
most of the mutant Arg 5°5 ~ Gin /3 chains is likely unable 
to exit the endoplasmic reticulum. Similar clinical (adult 
form of Tay-Sachs disease) and biochemical phenotypes 
have been reported to result from a HEXA gene mutation. 
This mutation, a Gly 269---~ Ser substitution, results in a 
significant level of heat-labile Hex A in transfected COS 
cells [23], but only low levels of expression (4-6% of 
normal) in patient cells [24]. 
Our study brings into question the previous conclusion 
regarding the impact of the A 6~9 ~ G mutation. Banerjee 
and coworkers [6] first suggested that the A 6~9 ~ G transi- 
tion results in impaired GM2 activator protein binding. 
Then, the same authors proposed that the A 619 ~ G muta- 
tion leads to slow self-association f the mutant fl-chains, 
which results in the inability to produce active Hex B only 
when the /3-chain is expressed at low concentration by a 
second mutant HEXB allele [10]. 
Our observation and that of Banerjee and colleagues 
share the following point: patients who are heterozygotes 
for the A 6~9 ~ G mutation (i.e., the patient's father in the 
Banerjee's report and our subject II-1) are asymptomatic 
and express normal levels of Hex B activity and /3-CRM. 
Therefore, the possibility that this mutation has a deleteri- 
ous effect on the active site of /3-Hex can be excluded. 
When the A 619 --* G allele is expressed in the homozy- 
gous form, two pathophysiological hypotheses can be con- 
sidered. First, as suggested by Banerjee and coworkers 
[10], even in the homozygous form, the A619~ G allele 
might still produce a functional Hex B if the mutation in 
the other allele does not reduce the effective /3-chain 
concentration below some critical level. Indeed, the G 1514 
A transition (present in one of individual I-I alleles 
along with A 619 --* G) has not been reported to affect the 
concentration of /3-chains in transfected COS cells, but to 
result in a tbermo-labile Hex B [9]. However, as previously 
discussed our data indicate that in patients' cells the 
/3-chains carrying this ArgS°5 ~ Gin substitution are re- 
tained and rapidly degraded, just as the /3-chains carrying 
the Tyr 456-~ Ser substitution were reported to do by 
Banerjee et al. [6]. Thus, the situation in the homozygous 
(A 619 --* G, Ile 2°7 --* Val) father, also heterozygous for 
G 1514 ---) A (Arg 5°5 -~ Gln), is very similar to the patient 
described by Banerjee t al. (heterozygous for both A 619 -* 
G (Ile 2°7 ~ Val) and A 1367 ~ C (Tyr 456 -~ Ser)), and based 
on their hypothesis, the majority of mutant /3-chains would 
not be expected to self-associate and exit the endoplasmic 
reticulum. However, our data clearly indicate that neither 
/3-Hex B activity nor mature, lysosomal /3-CRM is lower 
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than would be expected for carriers of Sandhoff disease in 
cells from either parent, only one of whom (the father I-1) 
is homozygote for the A 619 ---)' G mutation. 
From the above data, we concluded that the most likely 
possibility is that the A619~ G mutation represents a
neutral substitution mutation. Two other lines of research 
conclusively proved this hypothesis. Firstly, an extensive 
review of the literature revealed a recent report hat identi- 
fied the mother of a patient with infantile Sandhoff disease 
as being a compound heterozygote for the A 619 -~ G muta- 
tion and for a novel 50 kb deletion [25]. Because the focus 
of this report was on characterizing the novel 50 kb 
deletion, the authors did not recognize this substitution as 
being identical to the one previously reported to cause 
adult Sandhoff disease by Banerjee et al. Thus, the impor- 
tance of their observation i  this respect was not reported. 
According to Banerjee's hypothesis [6,10], this woman 
should have been affected as severely as their Sandhoff 
patient because of the presence of a second totally non- 
functional mutant HEXB allele. However, this woman was 
asymptomatic [25]. In addition, we inquired into the levels 
of /3-Hex activity in white blood cells of this woman 
which were not reported by Zhang et al. Whereas they 
were slightly outside the lower range for carriers (still far 
higher than for affected patients), levels in serum were 
within the expected range (G.H. Thomas, personal commu- 
nication), suggesting little or no effect of the A6~9~ G 
mutation. Coupled with the activity and Western blot data 
we report for our patients' family, this demonstrates that 
the A 6j9---> G has little or no effect on the functions or 
levels of the Hex isoenzymes regardless of the identity of 
the second HEXB allele, and that it has no similarity to 
any of the TaT-Sachs pseudo-deficiency mutations de- 
scribed in the HEXA gene [1]. Secondly, we investigated 
15 normal adult individuals and found this allele to be 
present in the heterozygous form in two, and homozygous 
form in one subject (data not shown). Thus, the A 6~9 ~ G 
substitution is clearly a neutral mutation which is also a 
common HEXB polymorphism, and the G ]514 ---> A transi- 
tion appears olely responsible for the late-onset form of 
Sandhoff disease. 
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